Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Immunotherapeutic effects of intratumoral nanoplexed poly I:C.

Aznar MA, Planelles L, Perez-Olivares M, Molina C, Garasa S, Etxeberría I, Perez G, Rodriguez I, Bolaños E, Lopez-Casas P, Rodriguez-Ruiz ME, Perez-Gracia JL, Marquez-Rodas I, Teijeira A, Quintero M, Melero I.

J Immunother Cancer. 2019 May 2;7(1):116. doi: 10.1186/s40425-019-0568-2.

2.

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.

Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, de Andrea C, Rodriguez-Ruiz ME, Perez-Gracia JL, Marquez-Rodas I, Llacer C, Alvarez M, de Luque V, Molina C, Teijeira A, Berraondo P, Melero I.

Nature. 2019 May;569(7756):428-432. doi: 10.1038/s41586-019-1162-y. Epub 2019 May 1.

PMID:
31043740
3.

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.

Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, Berraondo P, Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M, Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia JL, Melero I.

Nat Med. 2019 Mar;25(3):470-476. doi: 10.1038/s41591-018-0339-5. Epub 2019 Feb 11.

PMID:
30742120
4.

TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies.

Rodríguez-Ruiz ME, Rodríguez I, Mayorga L, Labiano T, Barbes B, Etxeberria I, Ponz-Sarvise M, Azpilikueta A, Bolaños E, Sanmamed MF, Berraondo P, Calvo FA, Barcelos-Hoff MH, Perez-Gracia JL, Melero I.

Mol Cancer Ther. 2019 Mar;18(3):621-631. doi: 10.1158/1535-7163.MCT-18-0558. Epub 2019 Jan 25.

PMID:
30683810
5.

Time for radioimmunotherapy: an overview to bring improvements in clinical practice.

Leaman Alcibar O, Candini D, López-Campos F, Albert Antequera M, Morillo Macías V, Conde AJ, Rodríguez Pérez A, Hervás Morón A, Contreras Martínez J, Ferrer Albiach C, Navarro Aguilar S, Rodríguez-Ruiz ME.

Clin Transl Oncol. 2019 Aug;21(8):992-1004. doi: 10.1007/s12094-018-02027-1. Epub 2019 Jan 14. Review.

PMID:
30644044
6.

Immune mechanisms mediating abscopal effects in radioimmunotherapy.

Rodriguez-Ruiz ME, Rodriguez I, Leaman O, López-Campos F, Montero A, Conde AJ, Aristu JJ, Lara P, Calvo FM, Melero I.

Pharmacol Ther. 2019 Apr;196:195-203. doi: 10.1016/j.pharmthera.2018.12.002. Epub 2018 Dec 5. Review.

PMID:
30529041
7.

Cytokines in clinical cancer immunotherapy.

Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I.

Br J Cancer. 2019 Jan;120(1):6-15. doi: 10.1038/s41416-018-0328-y. Epub 2018 Nov 9. Review.

PMID:
30413827
8.

Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.

Sánchez-Paulete AR, Teijeira Á, Quetglas JI, Rodríguez-Ruiz ME, Sánchez-Arráez Á, Labiano S, Etxeberria I, Azpilikueta A, Bolaños E, Ballesteros-Briones MC, Casares N, Quezada SA, Berraondo P, Sancho D, Smerdou C, Melero I.

Cancer Res. 2018 Dec 1;78(23):6643-6654. doi: 10.1158/0008-5472.CAN-18-0933. Epub 2018 Oct 8.

PMID:
30297531
9.

A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis.

Rodriguez J, Castañón E, Perez-Gracia JL, Rodriguez I, Viudez A, Alfaro C, Oñate C, Perez G, Rotellar F, Inogés S, López-Diaz de Cerio A, Resano L, Ponz-Sarvise M, Rodriguez-Ruiz ME, Chopitea A, Vera R, Melero I.

J Immunother Cancer. 2018 Sep 29;6(1):96. doi: 10.1186/s40425-018-0405-z.

10.

International Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, Spain.

Berraondo P, Aznar MA, Perez-Ruiz E, Rodriguez-Ruiz ME, Castañon E, Perez-Gracia JL, Melero I.

Cancer Immunol Immunother. 2018 Nov;67(11):1809-1813. doi: 10.1007/s00262-018-2240-y. Epub 2018 Sep 4. No abstract available.

PMID:
30182281
11.

Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect.

Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S.

Trends Immunol. 2018 Aug;39(8):644-655. doi: 10.1016/j.it.2018.06.001. Epub 2018 Jul 11. Review.

12.

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.

Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, Alfaro C, Oñate C, Pérez G, Gil-Bazo I, Benito A, Inogés S, López-Diaz de Cerio A, Ponz-Sarvise M, Resano L, Berraondo P, Barbés B, Martin-Algarra S, Gúrpide A, Sanmamed MF, de Andrea C, Salazar AM, Melero I.

Ann Oncol. 2018 May 1;29(5):1312-1319. doi: 10.1093/annonc/mdy089.

PMID:
29554212
13.

Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).

Azpilikueta A, Bolaños E, Lang V, Labiano S, Aznar MA, Etxeberria I, Teijeira A, Rodriguez-Ruiz ME, Perez-Gracia JL, Jure-Kunkel M, Zapata JM, Rodriguez MS, Melero I.

Oncoimmunology. 2017 Sep 21;7(1):e1368605. doi: 10.1080/2162402X.2017.1368605. eCollection 2017.

14.

Interleukin-8 in cancer pathogenesis, treatment and follow-up.

Alfaro C, Sanmamed MF, Rodríguez-Ruiz ME, Teijeira Á, Oñate C, González Á, Ponz M, Schalper KA, Pérez-Gracia JL, Melero I.

Cancer Treat Rev. 2017 Nov;60:24-31. doi: 10.1016/j.ctrv.2017.08.004. Epub 2017 Aug 31. Review.

PMID:
28866366
15.

Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies.

Rodriguez-Ruiz ME, Rodriguez I, Barbes B, Mayorga L, Sanchez-Paulete AR, Ponz-Sarvise M, Pérez-Gracia JL, Melero I.

Brachytherapy. 2017 Nov - Dec;16(6):1246-1251. doi: 10.1016/j.brachy.2017.06.012. Epub 2017 Aug 21.

PMID:
28838649
16.

Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.

Pérez-Ruiz E, Etxeberria I, Rodriguez-Ruiz ME, Melero I.

Clin Cancer Res. 2017 Sep 15;23(18):5326-5328. doi: 10.1158/1078-0432.CCR-17-1799. Epub 2017 Aug 8.

17.

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.

Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I.

Ann Oncol. 2017 Aug 1;28(8):1988-1995. doi: 10.1093/annonc/mdx190.

18.

Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I.

Cancer Treat Rev. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Epub 2016 Dec 30. Review.

19.

Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium.

Rodriguez-Ruiz ME, Garasa S, Rodriguez I, Solorzano JL, Barbes B, Yanguas A, Teijeira A, Etxeberria I, Aristu JJ, Halin C, Melero I, Rouzaut A.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):389-400. doi: 10.1016/j.ijrobp.2016.10.043. Epub 2016 Nov 7.

PMID:
28068246
20.

Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally.

Aznar MA, Tinari N, Rullán AJ, Sánchez-Paulete AR, Rodriguez-Ruiz ME, Melero I.

J Immunol. 2017 Jan 1;198(1):31-39. Review.

21.

Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy.

Melero I, Berraondo P, Rodríguez-Ruiz ME, Pérez-Gracia JL.

Cancer Discov. 2016 Dec;6(12):1312-1314.

22.

Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.

Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S, Sanmamed MF, Azpilikueta A, Bolaños E, Sanchez-Paulete AR, Aznar MA, Rouzaut A, Schalper KA, Jure-Kunkel M, Melero I.

Cancer Res. 2016 Oct 15;76(20):5994-6005. Epub 2016 Aug 22.

23.

Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.

Alegre E, Fusco JP, Restituto P, Salas-Benito D, Rodríguez-Ruiz ME, Andueza MP, Pajares MJ, Patiño-García A, Pio R, Lozano MD, Gúrpide A, Lopez-Picazo JM, Gil-Bazo I, Perez-Gracia JL, Gonzalez A.

Tumour Biol. 2016 Oct;37(10):13687-13694. Epub 2016 Jul 29.

PMID:
27473086
24.

Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop.

Berraondo P, Ochoa MC, Rodriguez-Ruiz ME, Minute L, Lasarte JJ, Melero I.

Cancer Res. 2016 May 15;76(10):2863-7. doi: 10.1158/0008-5472.CAN-15-3279. Epub 2016 May 2.

25.

Emerging Opportunities and Challenges in Cancer Immunotherapy.

Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I.

Clin Cancer Res. 2016 Apr 15;22(8):1845-55. doi: 10.1158/1078-0432.CCR-16-0049. Review.

26.

Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?

Weigelin B, Bolaños E, Rodriguez-Ruiz ME, Martinez-Forero I, Friedl P, Melero I.

Cancer Immunol Immunother. 2016 May;65(5):493-7. doi: 10.1007/s00262-016-1818-5. Epub 2016 Mar 12.

PMID:
26970765
27.

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.

Azpilikueta A, Agorreta J, Labiano S, Pérez-Gracia JL, Sánchez-Paulete AR, Aznar MA, Ajona D, Gil-Bazo I, Larrayoz M, Teijeira A, Rodriguez-Ruiz ME, Pio R, Montuenga LM, Melero I.

J Thorac Oncol. 2016 Apr;11(4):524-36. doi: 10.1016/j.jtho.2016.01.013. Epub 2016 Feb 1.

28.

[Treatment of prostate cancer according to life expectancy, comorbidity and clinical practice guidelines].

Pérez-Gracia JL, Rodríguez Ruiz ME, Fusco JP, Gúrpide A.

An Sist Sanit Navar. 2015 Sep-Dec;38(3):463-4. Spanish. No abstract available.

29.

Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.

Sanchez-Paulete AR, Labiano S, Rodriguez-Ruiz ME, Azpilikueta A, Etxeberria I, Bolaños E, Lang V, Rodriguez M, Aznar MA, Jure-Kunkel M, Melero I.

Eur J Immunol. 2016 Mar;46(3):513-22. doi: 10.1002/eji.201445388. Epub 2016 Feb 9. Review.

30.

Functional expression of CD137 (4-1BB) on T helper follicular cells.

Alfaro C, Echeveste JI, Rodriguez-Ruiz ME, Solorzano JL, Perez-Gracia JL, Idoate MA, Lopez-Picazo JM, Sanchez-Paulete AR, Labiano S, Rouzaut A, Oñate C, Aznar A, Lozano MD, Melero I.

Oncoimmunology. 2015 May 29;4(12):e1054597. eCollection 2015 Dec.

31.

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.

Sánchez-Paulete AR, Cueto FJ, Martínez-López M, Labiano S, Morales-Kastresana A, Rodríguez-Ruiz ME, Jure-Kunkel M, Azpilikueta A, Aznar MA, Quetglas JI, Sancho D, Melero I.

Cancer Discov. 2016 Jan;6(1):71-9. doi: 10.1158/2159-8290.CD-15-0510. Epub 2015 Oct 22.

32.

Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.

Sanmamed MF, Pastor F, Rodriguez A, Perez-Gracia JL, Rodriguez-Ruiz ME, Jure-Kunkel M, Melero I.

Semin Oncol. 2015 Aug;42(4):640-55. doi: 10.1053/j.seminoncol.2015.05.014. Epub 2015 Jun 11. Review.

PMID:
26320067
33.

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.

Sanmamed MF, Rodriguez I, Schalper KA, Oñate C, Azpilikueta A, Rodriguez-Ruiz ME, Morales-Kastresana A, Labiano S, Pérez-Gracia JL, Martín-Algarra S, Alfaro C, Mazzolini G, Sarno F, Hidalgo M, Korman AJ, Jure-Kunkel M, Melero I.

Cancer Res. 2015 Sep 1;75(17):3466-78. doi: 10.1158/0008-5472.CAN-14-3510. Epub 2015 Jun 25.

34.

Pneumomediastinum as a complication of SABR for lung metastases.

Rodríguez-Ruiz ME, Arévalo E, Gil-Bazo I, Olarte García A, Valtueña G, Moreno-Jiménez M, Arbea-Moreno L, Aristu J.

Radiat Oncol. 2015 Jan 23;10:25. doi: 10.1186/s13014-015-0330-y.

35.

Phase II trial of image-based high-dose-rate interstitial brachytherapy for previously irradiated gynecologic cancer.

Martínez-Monge R, Cambeiro M, Rodríguez-Ruiz ME, Olarte A, Ramos LI, Villafranca E, Bascón N, Jurado M.

Brachytherapy. 2014 May-Jun;13(3):219-24. doi: 10.1016/j.brachy.2014.01.008. Epub 2014 Feb 20.

PMID:
24559794
36.

Orchestrating immune check-point blockade for cancer immunotherapy in combinations.

Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I.

Curr Opin Immunol. 2014 Apr;27:89-97. doi: 10.1016/j.coi.2014.01.002. Epub 2014 Jan 28. Review.

PMID:
24485523
37.

A proposal for the stratification of the risk of locoregional failure after surgical resection, perioperative high dose rate brachytherapy, and external beam irradiation: the University of Navarre predictive model.

Martínez-Monge R, Cambeiro M, Rodríguez-Ruiz ME, Ramos LI, San-Julián M, Alcalde J, Jurado M.

Brachytherapy. 2014 Jul-Aug;13(4):400-4. doi: 10.1016/j.brachy.2013.11.001. Epub 2013 Dec 2.

PMID:
24295964
38.

Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review.

Rodríguez-Ruiz ME, San Miguel I, Gil-Bazo I, Perez-Gracia JL, Arbea L, Moreno-Jimenez M, Aristu J.

Radiat Oncol. 2012 Mar 28;7:50. doi: 10.1186/1748-717X-7-50. Review.

39.

Comparison of limited-volume perioperative high-dose-rate brachytherapy and wide-field external irradiation in resected head and neck cancer.

Gaztañaga M, Pagola M, Cambeiro M, Rodriguez Ruiz ME, Aristu J, Montesdeoca N, Alcalde J, Martínez-Monge R.

Head Neck. 2012 Aug;34(8):1081-8. doi: 10.1002/hed.21874. Epub 2012 Jan 20.

PMID:
22267124

Supplemental Content

Loading ...
Support Center